Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives

Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing prevalence of this disease and of its aggressive form nonalcoholic steatohepatitis (NASH) will require novel therapeut...

Full description

Bibliographic Details
Main Authors:	Arab, Juan P., Karpen, Saul J., Dawson, Paul A., Arrese, Marco, Trauner, Michael
Format:	Online
Language:	English
Published:	John Wiley and Sons Inc. 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5191969/

id	pubmed-5191969
recordtype	oai_dc
spelling	pubmed-51919692017-01-18 Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives Arab, Juan P. Karpen, Saul J. Dawson, Paul A. Arrese, Marco Trauner, Michael Reviews Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing prevalence of this disease and of its aggressive form nonalcoholic steatohepatitis (NASH) will require novel therapeutic approaches to prevent disease progression to advanced fibrosis or cirrhosis and cancer. In recent years, bile acids have emerged as relevant signaling molecules that act at both hepatic and extrahepatic tissues to regulate lipid and carbohydrate metabolic pathways as well as energy homeostasis. Activation or modulation of bile acid receptors, such as the farnesoid X receptor and TGR5, and transporters, such as the ileal apical sodium‐dependent bile acid transporter, appear to affect both insulin sensitivity and NAFLD/NASH pathogenesis at multiple levels, and these approaches hold promise as novel therapies. In the present review, we summarize current available data on the relationships of bile acids to NAFLD and the potential for therapeutically targeting bile‐acid‐related pathways to address this growing world‐wide disease. (Hepatology 2017;65:350‐362) John Wiley and Sons Inc. 2016-08-04 2017-01 /pmc/articles/PMC5191969/ /pubmed/27358174 http://dx.doi.org/10.1002/hep.28709 Text en © 2016 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Arab, Juan P. Karpen, Saul J. Dawson, Paul A. Arrese, Marco Trauner, Michael
spellingShingle	Arab, Juan P. Karpen, Saul J. Dawson, Paul A. Arrese, Marco Trauner, Michael Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
author_facet	Arab, Juan P. Karpen, Saul J. Dawson, Paul A. Arrese, Marco Trauner, Michael
author_sort	Arab, Juan P.
title	Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
title_short	Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
title_full	Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
title_fullStr	Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
title_full_unstemmed	Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
title_sort	bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives
description	Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing prevalence of this disease and of its aggressive form nonalcoholic steatohepatitis (NASH) will require novel therapeutic approaches to prevent disease progression to advanced fibrosis or cirrhosis and cancer. In recent years, bile acids have emerged as relevant signaling molecules that act at both hepatic and extrahepatic tissues to regulate lipid and carbohydrate metabolic pathways as well as energy homeostasis. Activation or modulation of bile acid receptors, such as the farnesoid X receptor and TGR5, and transporters, such as the ileal apical sodium‐dependent bile acid transporter, appear to affect both insulin sensitivity and NAFLD/NASH pathogenesis at multiple levels, and these approaches hold promise as novel therapies. In the present review, we summarize current available data on the relationships of bile acids to NAFLD and the potential for therapeutically targeting bile‐acid‐related pathways to address this growing world‐wide disease. (Hepatology 2017;65:350‐362)
publisher	John Wiley and Sons Inc.
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5191969/
_version_	1613833313589395456

Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives

Similar Items